Patents by Inventor Hea Jin Kim

Hea Jin Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220047670
    Abstract: The present invention relates to a method for treating autism spectrum disorder, a mouse for monitoring autism spectrum disorder, and a method for screening a candidate for preventing or treating autism spectrum disorder. Specifically, according to the present invention, the output signal (or excitation of population) of neurons of the ventrolateral thalamus (VL), the laterodorsal thalamus (LD) or the striatum may be suppressed by introducing a halorhodopsin protein into neurons of the ventrolateral thalamus (VL), the laterodorsal thalamus (LD) or the striatum and then irradiating light to induce hyperpolarization of the halorhodopsin protein. Thus, the present invention has the effect of preventing or treating autism.
    Type: Application
    Filed: November 13, 2019
    Publication date: February 17, 2022
    Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Jeongjin KIM, Hea-jin KIM, Yuliia STESHENKO, Sejin JEON, Hyunsoo PARK, Wooyeon SHIN
  • Publication number: 20200005169
    Abstract: A system for predicting an emotion of a user by using a web content includes a URL collection unit for collecting a URL of a web page; a representative URL selection unit for selecting a category-specific representative URL, a basic emotion-specific representative URL, and a dimensional emotion-specific representative URL according to contents included in a plurality of collected URLs; a representative vocabulary set creation unit for creating vocabulary sets representing a category, a basic emotion, and a dimensional emotion, respectively, on the basis of the selected representative URLs; a vocabulary extraction unit for crawling a plurality of texts; and a selection unit for comparing document similarities between the plurality of extracted vocabularies and the vocabulary sets.
    Type: Application
    Filed: February 1, 2017
    Publication date: January 2, 2020
    Applicant: SANGMYUNG UNIVERSITY INDUSTRY-ACADEMY COOPERATION FOUNDATION
    Inventors: Min Cheol WHANG, Young Ho JO, Hea Jin KIM
  • Patent number: 8883751
    Abstract: Disclosed is a radiation sensitivity-enhancing composition in which a microRNA-21 inhibitor acts as an active ingredient. The microRNA-21 inhibitor is an antisense nucleic acid molecule binding complementarily to microRNA-21. The composition can be administered to a patient in conjunction with irradiation. The inhibitor can act as a radiosensitizer, enhancing the therapeutic effect of such irradiation on cancer high in microRNA-21 expression level, particularly, glioma.
    Type: Grant
    Filed: July 30, 2008
    Date of Patent: November 11, 2014
    Assignee: National Cancer Center
    Inventors: Jong Bae Park, Seung Hoon Lee, Hee Jin Kwak, Tae Hoon Kim, Heon Yoo, Donghee Lee, Eun Kyoung Park, Hea Jin Kim
  • Publication number: 20110124712
    Abstract: Disclosed is an anticancer composition for the treatment of hypoxia-induced angiogenesis-associated diseases including cancers. It comprises a microRNA-125 nucleic acid molecule. Also, methods of inhibiting angiogenesis, suppressing the invasion and metastasis of cancer cells, and treating cancers are provided.
    Type: Application
    Filed: July 25, 2008
    Publication date: May 26, 2011
    Applicant: NATIONAL CANCER CENTER
    Inventors: Jong Bae Park, Seung Hoon Lee, Eun Kyoung Park, Donghee Lee, Hee-Seok Yang, Heon Yoo, Hea Jin Kim, Tae Hoon Kim, Hee Jin Kwak
  • Publication number: 20110021601
    Abstract: Disclosed is a radiation sensitivity-enhancing composition in which a microRNA-21 inhibitor acts as an active ingredient. The microRNA-21 inhibitor is an antisense nucleic acid molecule binding complementarily to microRNA-21. The composition can be administered to a patient in conjunction with irradiation. The inhibitor can act as a radiosensitizer, enhancing the therapeutic effect of such irradiation on cancer high in microRNA-21 expression level, particularly, glioma.
    Type: Application
    Filed: July 30, 2008
    Publication date: January 27, 2011
    Applicant: NATIONAL CANCER CENTER
    Inventors: Jong Bae Park, Seung Hoon Lee, Hee Jin Kwak, Tae Hoon Kim, Heon Yoo, Donghee Lee, Eun Kyoung Park, Hea Jin Kim